Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies
March 21, 2026, 9:36 pm
Location: United Kingdom
Employees: 11-50
Founded date: 2020
Total raised: $75.99M
Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-2026. The funds also advance its innovative platform for inflammatory diseases. New leadership appointments strengthen the team, preparing for clinical progress.
Mestag Therapeutics, a leader in fibroblast immunology, recently closed a $40 million financing round. This latest capital infusion elevates the company's total funding. Mestag has now raised over $95 million. This substantial investment underscores confidence in its pioneering approach. The financing round saw participation from prominent investors. SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (Google Ventures), and Northpond Ventures all contributed. These backers recognize Mestag's potential.
The capital will primarily drive a critical oncology program. The Phase 1 STARLYS clinical study is a major focus. This trial evaluates MST-0312. MST-0312 is a FAP-targeted LTBR agonist bispecific antibody. It represents a novel mechanism of action. The study is slated to begin in mid-2026. It will enroll cancer patients. This marks a significant step towards human trials.
Fibroblast immunology forms Mestag's core. Fibroblasts are crucial cells. They shape the tissue microenvironment. This environment influences disease progression. Especially in cancer and inflammatory conditions. Mestag's therapies target these stromal cells. They aim to reprogram disease states. This offers a distinct therapeutic avenue. It moves beyond traditional immune cell targeting.
MST-0312 specifically targets the tumor microenvironment. It focuses on Tertiary Lymphoid Structures (TLSs). TLSs are immune cell clusters within solid tumors. They are vital for anti-tumor immunity. Their presence often correlates with improved patient outcomes. MST-0312 aims to induce these structures. It also targets High Endothelial Venules (HEV). HEV facilitate immune cell entry into tumors. Enhancing TLS and HEV formation could turn "cold" tumors "hot." This makes them responsive to immunotherapy. MST-0312 offers hope for cancers resistant to current treatments.
Beyond oncology, Mestag maintains a robust inflammatory disease pipeline. The M402 program is a key asset. M402 is an agonist antibody. It targets a stromal inhibitory receptor. Its goal is to dampen specific immune cell activation. This could offer relief in chronic inflammatory conditions. Earlier programs are also in discovery stages. These explore novel targets. Mestag's diverse pipeline addresses significant unmet medical needs.
The company's proprietary RAFT Platform is central to its innovation. RAFT stands for Fibroblast-immune RAFT Platform. This specialist platform identifies novel therapeutic targets. It leverages advanced understanding of fibroblast biology. The platform supports both cancer and inflammatory disease programs. It provides a continuous stream of potential new therapies. This strategic asset ensures sustained pipeline growth.
Mestag has also forged key strategic collaborations. These partnerships validate its scientific approach. In 2024, Mestag entered a license and research collaboration with MSD. MSD is known as Merck & Co. in the USA. This collaboration identifies novel targets for inflammatory diseases. It expands Mestag's reach. A prior 2021 agreement also saw Mestag license a novel target to Johnson & Johnson. This occurred through Janssen Biotech, Inc. Such collaborations amplify Mestag's impact. They accelerate drug discovery. They also provide significant external validation.
Executive leadership has been strengthened. Mestag announced two pivotal appointments. Lindsey Rolfe, BSc, MBChB, MRCP, FFPM, joins as Chief Medical Officer. She brings over 30 years of clinical and regulatory experience. Her expertise spans global development and regulatory approval. Dr. Rolfe held prior leadership roles at Clovis Oncology and 3B Pharmaceuticals. Her insights will guide clinical program advancement.
Pascal Merchiers, PhD, assumes the role of Chief Development Officer. He contributes more than 25 years of experience. His background covers drug discovery and development. He has worked across multiple biotech organizations. These include Commit Biologics, Aboleris, and Tusk Therapeutics. Dr. Merchiers will drive development activities. He will oversee the innovative pipeline. These appointments ensure seasoned leadership. They are crucial for upcoming clinical milestones.
Mestag's strategic vision is clear. It aims to develop impactful antibody therapeutics. These target both cancer and inflammatory disease. The company's focus on fibroblast immunology distinguishes it. This emerging field holds vast potential. Mestag positions itself at the forefront. Its innovative science addresses fundamental disease mechanisms.
This new financing provides significant operational runway. It enables clinical execution. It supports platform expansion. The company moves closer to its mission. That mission is to bring groundbreaking treatments to patients. These treatments promise improved outcomes. They offer new hope. Mestag continues its journey. It transforms scientific understanding into clinical reality. The biotech sector watches closely. Its innovative approach may redefine therapeutic standards. Expectations are high for its clinical advancements.
Mestag Therapeutics, a leader in fibroblast immunology, recently closed a $40 million financing round. This latest capital infusion elevates the company's total funding. Mestag has now raised over $95 million. This substantial investment underscores confidence in its pioneering approach. The financing round saw participation from prominent investors. SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (Google Ventures), and Northpond Ventures all contributed. These backers recognize Mestag's potential.
The capital will primarily drive a critical oncology program. The Phase 1 STARLYS clinical study is a major focus. This trial evaluates MST-0312. MST-0312 is a FAP-targeted LTBR agonist bispecific antibody. It represents a novel mechanism of action. The study is slated to begin in mid-2026. It will enroll cancer patients. This marks a significant step towards human trials.
Fibroblast immunology forms Mestag's core. Fibroblasts are crucial cells. They shape the tissue microenvironment. This environment influences disease progression. Especially in cancer and inflammatory conditions. Mestag's therapies target these stromal cells. They aim to reprogram disease states. This offers a distinct therapeutic avenue. It moves beyond traditional immune cell targeting.
MST-0312 specifically targets the tumor microenvironment. It focuses on Tertiary Lymphoid Structures (TLSs). TLSs are immune cell clusters within solid tumors. They are vital for anti-tumor immunity. Their presence often correlates with improved patient outcomes. MST-0312 aims to induce these structures. It also targets High Endothelial Venules (HEV). HEV facilitate immune cell entry into tumors. Enhancing TLS and HEV formation could turn "cold" tumors "hot." This makes them responsive to immunotherapy. MST-0312 offers hope for cancers resistant to current treatments.
Beyond oncology, Mestag maintains a robust inflammatory disease pipeline. The M402 program is a key asset. M402 is an agonist antibody. It targets a stromal inhibitory receptor. Its goal is to dampen specific immune cell activation. This could offer relief in chronic inflammatory conditions. Earlier programs are also in discovery stages. These explore novel targets. Mestag's diverse pipeline addresses significant unmet medical needs.
The company's proprietary RAFT Platform is central to its innovation. RAFT stands for Fibroblast-immune RAFT Platform. This specialist platform identifies novel therapeutic targets. It leverages advanced understanding of fibroblast biology. The platform supports both cancer and inflammatory disease programs. It provides a continuous stream of potential new therapies. This strategic asset ensures sustained pipeline growth.
Mestag has also forged key strategic collaborations. These partnerships validate its scientific approach. In 2024, Mestag entered a license and research collaboration with MSD. MSD is known as Merck & Co. in the USA. This collaboration identifies novel targets for inflammatory diseases. It expands Mestag's reach. A prior 2021 agreement also saw Mestag license a novel target to Johnson & Johnson. This occurred through Janssen Biotech, Inc. Such collaborations amplify Mestag's impact. They accelerate drug discovery. They also provide significant external validation.
Executive leadership has been strengthened. Mestag announced two pivotal appointments. Lindsey Rolfe, BSc, MBChB, MRCP, FFPM, joins as Chief Medical Officer. She brings over 30 years of clinical and regulatory experience. Her expertise spans global development and regulatory approval. Dr. Rolfe held prior leadership roles at Clovis Oncology and 3B Pharmaceuticals. Her insights will guide clinical program advancement.
Pascal Merchiers, PhD, assumes the role of Chief Development Officer. He contributes more than 25 years of experience. His background covers drug discovery and development. He has worked across multiple biotech organizations. These include Commit Biologics, Aboleris, and Tusk Therapeutics. Dr. Merchiers will drive development activities. He will oversee the innovative pipeline. These appointments ensure seasoned leadership. They are crucial for upcoming clinical milestones.
Mestag's strategic vision is clear. It aims to develop impactful antibody therapeutics. These target both cancer and inflammatory disease. The company's focus on fibroblast immunology distinguishes it. This emerging field holds vast potential. Mestag positions itself at the forefront. Its innovative science addresses fundamental disease mechanisms.
This new financing provides significant operational runway. It enables clinical execution. It supports platform expansion. The company moves closer to its mission. That mission is to bring groundbreaking treatments to patients. These treatments promise improved outcomes. They offer new hope. Mestag continues its journey. It transforms scientific understanding into clinical reality. The biotech sector watches closely. Its innovative approach may redefine therapeutic standards. Expectations are high for its clinical advancements.